cells so that we are now in a position to propose recommendations to those wishing to establish their own cell line.
In general the criteria are concerned with obtaining uncontaminated tissue from a normal person, proving its normality throughout its finite life and showing that extraneous agents or untoward reactions are not likely to occur in use. Many of the tests may seem somewhat tedious but there are no tests proposed for a new cell substrate that have not been satisfied already by the WI-38 cell line.
Even though the use of a standardized cell substrate may reduce the number of monkeys killed in order to produce monkey kidney cell cultures, the reduction in total number of monkeys required for medical research will be insignificant. The majority are used for the testing of vaccines and nothing can replace the need for animal tests in this respect.
The President: Is there, in this system, an opportunity for producing vaccines which so far we have not been able to produce? Dr F T Perkins: I think that one of the biggest developments will be in rabies vaccine. Rabies so far has had to be produced in the brains of animals, since the virus will grow only in that site. Using brain tissue for inoculation of humans is highly dangerous. The only development which has been made is to use suckling animals before the dangerous component of the brain develops. But there are some very exciting developments in the production of a rabies vaccine in these human diploid cells. The experimental vaccines have now been shown in monkeys and in dogs to protect the animals against street virus. I think it is particularly pertinent for us to mention this having in mind the accident which recently occurred in this country; we cannot lose sight of the desirability of having an effective and safe rabies vaccine in the United Kingdom.
Mr W J Perkins (National Institute for Medical Research, Mill Hill, London NW7)
Application of Computers in Association with Animal Experiments
In many cases of animal experiments in medical research, animals are used as models of human behaviour. They satisfy two criteria for modelling in that they resemble the ultimate system being studied and biomedical research workers are familiar with animal systems. In the final application to human systems, as with the long-term sideeffects of drugs, some human experiments may be necessary. The pattern is to study lower order systems for the initial experiments and the question is whether we really start low enough. Simple systems may be described mathematically with the equations implemented on a computer, to simulate their behaviour. Assuming for the moment that simulation is a valuable method, and I hope the moon landings have indicated this, biomedical workers will need to familiarize themselves with the appropriate mathematical techniques if they are to use computers as lower order models. As computers can deal with the solution of equations, the research worker has the less difficult task of formulating his ideas into equations. These models may be used at the early stage of an initial hypothesis to test ideas and act as a guide to those animal experiments most likely to provide useful information.
Once a model has been validated for a particular usage, it may also provide an alternative to difficult internal measurement by calculation from simple external measurement.
Results from experimental data often need to be processed and analysed before any conclusions may be drawn and it is at this stage that defects in the experimental procedures might be found. Where a computer can be used on-line to an experiment, the processed output may be obsetved immediately and appropriate action taken on the one experiment.
Comparing any two variables of n parameters could involve a number of experiments upon different animals. Here the experimental procedures are elaborated in order to simplify the analysis. An alternative could be to measure all n variables in the one experiment, producing simple and probably more effective dynamic measurements but necessitating a far more complex procedure for the analysis. However, there are sophisticated mathematical techniques that may be used in association with computers to provide information from data.
Computers may be used before, during and after animal experiments and could possibly help in reducing the number of animals used.
Professor G M Wilson
(University Department ofMedicine, Western Infirmary, Glasgow WI)
The Experimental Trial of New Drugs in Man As a medical student in 1939 I was taught that the correct and most effective method of treating acute anuric renal failure was the intravenous infusion of sodium sulphate in normal saline (Dunlop et al. 1939) . The certainty of this statement was emphasized by quoting the strength of sodium sulphate to three decimal places, 4-285 %. This therapeutic advice was based on observations in animals; it had never been subjected to properly designed experimental trial in human patients. Subsequently during the war I saw several severely injured servicemen subjected to this treatment which is now realized to be not only useless in the treatment of anuria but actually harmful (Bull 1955) . The suggestion that a scientifically designed experiment should be carried out involving these soldiers severely wounded in the service of their country would have been regarded as repugnant and quite unacceptable at the time. However, if it had been done I have often reflected how fortunate the 'controls' might have been and how many lives might have been saved. This is an example of what is now much more widely recognized, that the results of experiments in laboratory animals cannot be applied directly to the treatment of disease in man. 'Applied pharmacology' has been rightly condemned by Pickering (1949) as no substitute for properly designed investigations in man. In the case of a new drug the aim of the investigator must be to determine the efficacy and safety of the preparation as rapidly as possible with the minimum of risk to those taking part in the trial. This is no easy task.
There are essentially three stages in the experimental investigation of a new drug in man. The first is concerned with the clinical pharmacology of the agent, the second with the determination of its therapeutic value and the third with adverse reactions. From the scientificviewpoint the clinical pharmacology is the easiest stage, though the ethical difficulties are often greatest when the potentiality of the drug in man is quite unknown.
Clinical Pharmacology
Before a drug is first given to man extensive testing has to be carried out in laboratory animals and in this way much information has been gained about its pharmacological action, carriage in the blood stream, distribution in the mammalian body, metabolism and excretion. These results must be confirmed in man as considerable species differences often exist. In particular, the effective dose range has to be established. This is best done in association with determinations of plasma concentration of the drug though unfortunately this is often impossible as suitable methods of measurement are usually not available. Nevertheless increasing attention must be paid to the development of these techniques, as information on plasma concentrations is of fundamental importance in clinical pharmacological investigations.
The considerations that arise when a drug is first given to man have been fully discussed by Laurence (1964) . Particular attention must be paid to safety and to the choice of subjects. It is axiomatic that the clinical investigator should have studied fully and understood all the preclinical evidence; a discussion with the scientists who have carried out this work is most valuable. The initial administration of the drug should take place in a properly equipped laboratory in the presence of fully trained staff. The choice of subjects for these initial studies is never easy. They may be healthy subjects or patients. If the latter are in Britain, approval of the Committee on Safety of Drugs must first have been given for the clinical trial of the drug but no such safeguard exists for the former. Much must depend on the nature of the drug and the information that is most urgently required. The pharmacological action of many drugs can readily be investigated in healthy subjects, for example a diuretic or hypotensive agent produces measurable changes. The effect of an analgesic or tranquillizer is not so easily demonstrated, but valuable information may be obtained regarding absorption, metabolism, urinary excretion and so on.
Some of the most difficult ethical questions arise at this stage of the experimental investigation of a new drug. The therapeutic value of the drug is unknown and studies of clinical pharmacology are not designed primarily to help the recipient. Often the first experimental subjects are clinical investigators or medical students but they may be patients in hospital. There is much to be said for the senior investigator himself taking the drug if other healthy subjects are subsequently to be involved. Certain drugs such as cytotoxic agents can only legitimately be given initially to patients suffering from the disease to be treated but inevitably at this preliminary stage the initial doses will be small and possibly ineffective. Fortunately much thought has been given in recent years to these problems and there are several publications to guide the clinical research worker (Medical Research Council 1963 , World Medical Association 1964 . The proposed investigation should always be reviewed by a medical ethical committee of colleagues in the hospital.
Therapeutic Trials
Once the activity and appropriate dose of a new drug has been established by these preliminary investigations in man the therapeutic value must be investigated. Because a drug has definite pharmacological actions in man therapeutic activity does not necessarily follow. For example, a drug that possesses peripheral vasodilator activity may not have any beneficial effect in the treatment of intermittent claudication. The principles governing the design of clinical therapeutic trials have been fully described by Bradford Hill (1967) and need not be elaborated in detail here. How-ever, there are a few points that I should like to stress.
Sir Henry Dale has pointed out that 'all true measurement is essentially comparative' and nowhere does this apply more than in clinical trials of new drugs. The basis of the trial is a valid comparison contrasting the new approach with what is considered the best previously available. This should raise no ethical problems as in serious disease patients are not being deprived of treatment. The aim of the trial must always be to establish as reliably and quickly as possible how the new method stands in relation to the old. As soon as this becomes apparent patients must be given the better treatment. Platt (1963) has stated that probably in a majority of therapeutic situations a controlled clinical trial is unnecessary, citing several instances including the modem treatment of malaria, meningococcal meningitis and thyrotoxicosis on the grounds that clinical and laboratory tests indicate rapidly whether the treatment is effective. This can certainly be accepted but observations of this type afford inadequate information. They do not answer questions uppermost in the clinician's mind such as, which course of treatment affords the best chance of avoiding a relapse of malaria? Is a sulphonamide or penicillin or some combination preferable in meningococcal meningitis, what is the value of intrathecal penicillin and what is the best dose? How do the different methods of treating thyrotoxicosis compare, and does the duration of drug therapy influence the chance of achieving a permanent remission?
In almost every aspect of therapeutics we are still lacking comparative information and this does not apply only to recently introduced methods. In some doctors' minds a 'controlled' trial seems to mean only a comparison of treated and untreated groups. For example, Platt (1963) has written: 'In some cases of dangerous disease where a specific remedy is thought to have been found, as for instance tetracyclines in typhus, the results, if of any use, will speak for themselves and no controlled trial is necessary.' However, the question might well arise as to the optimal dose of tetracycline and the duration of treatment. A similar situation arose when penicillin first became available for the treatment of subacute bacterial endocarditis. The initial results certainly spoke for themselves but control was exercised to ensure that valid comparisons could be made between different schedules of treatment to demonstrate which was the most effective (Cates & Christie 1951) .
The Use ofPlacebos Much controversy can arise over the use of pharmacologically inert preparations. They are clearly not indicated in clinical trials of new drugs in the treatment of dangerous diseases for which an effective remedy is already available. Other considerations arise when a drug for the symptomatic relief of pain, anxiety or insomnia is under investigation. These are conditions which cannot be measured accurately and thus the response is difficult to assess. They can be considerably modified by suggestion. In these circumstances an inert preparation is often required in the trial to demonstrate that any observed effect is due to the pharmacological action of the drug. Some patients who complain of insomnia are unable to distinguish regularly between an inert tablet and a barbiturate; in them no meaningful comparison could be made between an established and a new hypnotic.
In the investigation of the value of treatment of the mild forms of certain potentially serious diseases the experimental design may well have to include a group receiving an inert preparation. For example, there is much uncertainty about how to manage patients with low grade hypertension, say men aged about 50, symptomless but with a diastolic blood pressure of 100 to 105 mmHg. Would their outlook be improved by antihypertensive drugs or would the disadvantages associated with these agents be worse than the disease? In any attempt to solve this issue an untreated group is essential for comparison.
The Incidence ofAdverse Effects
The investigation of a new drug is not complete when the clinical pharmacology and therapeutic effectiveness have been establishedthough it might be regarded as no longer new by some once these stages had been completed. This does raise the question, how long is a new drug new? Fresh information continues to come in about drugs throughout their lifetime. This is certainly seen in relation to the contraceptive pill which has received more attention than any other preparation. There can be no end to the experimental trial of a drug as long as it is in use. This was most cogently expressed by Pickering (1949) who wrote: 'Therapeutics is the branch of medicine that, by its very nature, should be experimental. For if we take a patient afflicted with a malady, and we alter his conditions of life. . . by administering to him a drug ... we are performing an experiment. And if we are scientifically minded we should record the results.' I would submit to you that it is only by adopting this attitude of mind throughout the lifetime of a new drug that we can hope to gain precise knowledge of its place in therapeutics for good and ill.
Miss 0 Uvarov (Glaxo Laboratories): How do you assess the time which is required to know the good or weak characteristics of a drug after it has been launched? Also, how do you study in clinical trials the interaction of drugs?
Professor Wilson: I think you could say that we never seem to learn everything about a drug. We are still learning about aspirin and phenacetin and the harmful effects that these two drugs can produce. The more a drug is used, the more information comes to hand; I think it is impossible to draw an end-point here.
In relation to animal experiments and adverse effects, the main problem is that many of the most serious adverse effects occur only very seldom in man, say of the order of 1 in 10,000, and so you have to study a very large number of human beings before you pick up these adverse reactions. I do not think that this problem can be solved by trying to get more laboratory animals of different species. If we could learn more about the clinical pharmacology of the drug in the early stages in man, we might be better forewarned what to look for. This would possibly be a much more profitable approach.
As to the interaction of drugs, this is a difficult problem. Again, this is a matter of pharmacology. Animal experiments here could throw quite a lot of light on what to look for. In testing out a new drug in the first instance you should use it alone. Then, if you suspect that perhaps an interaction might occur, you can go on to design experiments which could show this. This is very much a matter of studying the pharmacology of the drug at an early stage both in animals and man to try to pinpoint any difficulties which might arise before going on to the clinical trial.
Dr R F Crampton: When the Committee on the Safety of Drugs receives toxicity data as an application for the institution of clinical trials, there is often some data on human volunteers. What weight do you put on this human data where it has shown that, say, the metabolism of a drug in the human volunteer bears some relationship to the metabolism of the drug on the main animal species on which the whole toxicity study has been done? Professor Wilson: I think we would put considerable weight on that. We are always very concerned to learn as quickly as possible what is the pathway of metabolism of a drug in man and how it compares with the animal data because the drug is designed to be used in man and that is the ultimate criterion. I personally feel that increasingly we must seek to get much more adequate information on the human pharmacology of drugs at a very early stage.
High Wycombe): Professor Wilson's paper left me slightly with the impression that one was faced with a choice between experiments involving small numbers of people (with high-quality experimental design) and experiments with large numbers (with poor-quality experimental design). I do not think that, in fact, one has to make this choice.
In certain fields experiments, of whatever quality, with small numbers of patients do not provide the answer. If one wants to find, for instance, an oral contraceptive with no aestrogen at all, one must prove its effectiveness. This cannot be done with small numbers of patients because we are talking about failure rates of the order of one in 1,000, perhaps, as the target one is aiming at. Similarly, the introduction of drugs for the management of minor diseases in general practice cannot be solved by the study of small numbers of patients in hospital. I believe that one of the important challenges of today is to improve the quality of the design of multicentre trials in general practice, to improve the quality of experiments involving large numbers of people, because I do not think there is any alternative to these experiments. An example has been the discovery of the rare condition of serious thromboembolic disease in users of oral contraceptives. The experimental design which proved this association was, in fact, an experimental design of a case control epidemiological study. I think that this is a good example of good experimental design, of an experiment where one has to look at large numbers of people. Professor Wilson: I do not think that Dr Venning and I are really in disagreement. In any experiment involving human beings one wants to use the smallest number that will give a result that is reliable. In some cases, you can demonstrate a new drug effect in a very small number if the quality of the work is high. However, I entirely agree that when looking for very infrequent effects, as indeed in thromboembolism and contraceptive agents, one has obviously to have very large numbers because these are very rare events. But you will only get this solution if you have both very large numbers and very high-quality work. Very large numbers alone will not give a satisfactory result if the reporting is poor and follow up of the cases inadequate.
Professor C E Dent (University College Hospital Medical School, London WCJ) An Experiment on a Baby with Idiopathic Hypercalcaemia A 9-month-old boy suffering from marasmus was diagnosed as having idiopathic hypercalcemia. An experiment investigating his possible sensitivity to vitamin D was carried out (Bonham-Carter et al. 1955 ) which led to a frightening deterioration of his clinical condition from which fortunately he made a complete recovery. The following features of this situation are considered fully to justify the ethics of this particular experiment:
(1) The infant was already suffering from a very serious chronic disease known to have a considerable mortality.
(2) The cause of the disease was not known at that time.
(3) There was at that time no known specific treatment.
(4) Previous studies had shown that the disease closely mimicked the state of vitamin D intoxica-tion, although sufficiently large doses of the vitamin had not usually been given to these patients. (5) It was therefore considered plausible to hypothesize that the infant (and others like him) was excessively sensitive to the vitamin D supplements taken with his diet. (6) If this were true the treatment would be to give the child for some months a vitamin D-free diet, and to keep him out of direct sunlight. This treatment could produce rickets if the theory were wrong, and in any case would be troublesome to insist on if we were not certain of its efficacy. (7) We could only check this theory by deliberately giving a moderate dose of vitamin D to the child to see what happened (in the event the child became very ill). (8) The child in question was expected to and did benefit in the end from a successful result to the experiment. (9) We explained the situation to the child's mother and obtained her consent verbally (nowadays we would obtain it written). (10) The entire investigation was done in the Metabolic Ward with careful supervision by a consultant pediatrician as well as a metabolist, and with repeated biochemical and clinical observation. (11) We had already worked out a method for preparing decalcified milk, the expected antidote to a possible vitamin D intoxication (Dent 1955 ). (12) The project was already along the lines of others being pursued in the same departments of University College Hospital, e.g. vitamin D sensitivity in sarcoidosis. (13) The results of the investigation were published for the benefit and warning of others.
While points 1, 3, 7, 8 and 9 are considered essential in justifying such a trial in a minor, the importance is stressed of ensuring that as many as possible of the other points raised should also be covered when possible, particularly No. 13 on occasions when the outcome is less happy.
